The Form 4 filing, an SEC report used to disclose insider stock trades, was filed on November 18, 2026. That was two days after the November 16 sale. The report identifies Adam Laponis as Twist Bioscience's chief financial officer.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-16 |
| Date of Latest Transaction | 2026-11-16 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 6,359 |
| Price | $103.69 |
| Total Transaction Value | $659,351.99 |
| Insider | |
| Ticker Symbol | TWST |
| Company | Twist Bioscience Corp |
| Insider Name | Laponis Adam |
| Insider Title | Chief Financial Officer |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 118,501 |
| Position Size Change | 5.09% |
| Filing | |
| Filing Date | 2026-11-18 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was one sale of Twist Bioscience Corp (TWST) shares. It was reported with transaction code S, which identifies a sale.
What was the average price of the transaction?
The average sale price was $103.69 per share, rounded to cents. That price applies to the shares in the one reported sale.
How did this transaction affect the insider's holdings?
Adam Laponis sold 6,359 shares and reported 118,501 shares owned afterward. The shares sold made up 5.09% of the shares he owned before the sale.
What's the total transaction value?
The total sale value was $659,351.99, rounded to cents, for 6,359 shares. That amount covers the single transaction dated November 16, 2026.
Are there any special circumstances around this transaction?
Yes. The available details point to a link with covering taxes on stock-based pay, meaning pay tied to company shares. The transaction uses sale code S. Filing footnotes were not provided, so the tax connection could not be checked against those notes. The exact tax purpose and any amount paid from the sale remain unknown.
For research purposes only; not investment advice.